Año 2019 / Volumen 111 / Número 5
Original
First approaches for the transplantation of hepatocytes from Wistar rat preneoplastic livers into healthy recipients

351-357

DOI: 10.17235/reed.2019.5830/2018

Marina Cecilia Vera, María Eugenia Biancardi, Hebe Bottai, María Cristina Lugano, Ariel Darío Quiroga, Gerardo Bruno Pisani, Alejandra Beatriz Quintana,

Resumen
Background: the shortage of donors of hepatocyte transplantation therapy led to the use of so-called marginal donors. Some donors may have a hepatic illnesses that is associated with hepatic preneoplasia with foci of altered hepatocytes (FAH). Aims: to determine whether recipients developed FAH upon transplantation with hepatocytes from a preneoplastic liver and whether FAH progresses to a preneoplastic hepatocyte-derived tumor (PHDT), up to 60 days after transplantation. Material and methods: male Wistar adult rats were used as donors and recipients. Donors underwent a 2-phase model of liver preneoplasia for hepatocyte isolation. Recipients underwent a partial two thirds hepatectomy and received 150,000 hepatocytes. Recipients were euthanized seven and 60 days after transplantation. The number of FAH per liver area, percentage of liver occupied by FAH, the hepatic enzymatic profile, the percentage of prothrombin time (PT), the proliferative index (PI) and liver morphology were analyzed. Results: recipients developed few and very isolated FAH. No statistical differences were found between hepatic enzyme activities and PT. There were no differences between the groups with regard to the number of FAH per liver area and percentage of liver occupied by FAH after 60 days. The PI decreased on day 60 compared to day seven. No morphological alterations were found. Conclusions: recipients developed few FAH that did not increase in number or size, nor did they progress to PHDT and had normal plasma biochemical features and liver morphology up to 60 days post-transplant. Additional studies are needed to determine whether FAH development constitutes a risk for recipients while waiting for whole organ transplant.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Gewartowska M, Olszewski WL. Hepatocyte transplantation-biology and application. Ann Transplant. 2007; 12:27-36.
2. Pareja E, Cortés M, Martínez A, et al. Hepatic Cellular Transplantation: a new treatment for hepatic illnesses. Cir Esp. 2010; 88:3-11.
3. Weber A, Groyer‐Picard MT, Franco D, et al. Hepatocyte transplantation in animal models. Liver Transpl. 2009; 15:7-14.
4. Pareja E, Martinez A, Cortés M, et al. Hepatic Cellular Transplantation: technical and methodological aspects. Cir Esp. 2010; 87:139-47.
5. Mito M, Kusano M, Kawaura Y. Hepatocyte transplantation in man. Cell Transplant. 1993; 2:65-74.
6. Gupta S. Hepatocyte Transplantation: New Strategies for Hepatic Transplantation and Gene Therapy. Indian J Gastroenterol. 1994; 13:13-23.
7. Henne-Bruns D, Krüger U, Sümpelmann D, et al. Intraperitoneal hepatocyte transplantation: Morphological results. Virchows Arch A Pathol Anat. 1991; 419:45-50.
8. Nagata H, Ito M, Shirota C, et al. Route of hepatocyte delivery affects hepatocyte engraftment in the spleen. Transplantation. 2003; 76:732-34.
9. Fondevila C, Jiménez-Galanes S, García-Valdecasas JC. How can the number of liver transplantations be increased? Gastroenterol Hepatol. 2013; 32:519-30.
10. Russo FP, Ferrarese A, Zanetto A. Recent advances in understanding and managing liver transplantation [version 1; referees: 3 approved] F1000Research 2016, 5(F1000 Faculty Rev):2895 (doi: 10.12688/f1000research.8768.1).
11. Michielsen P, Ho E. Viral hepatitis B and hepatocellular carcinoma. Acta Gastroenterol Belg. 2011; 74:4-8.
12. Cholankeril G, Patel R, Khurana S, et al. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. World J Hepatol. 2017; 9:533–43.
13. Institute for Laboratory Animal Research. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington, D.C.: National Academies Press; 2010. Guide for the Care and Use of Laboratory Animals, 8th edition.
14. Biancardi ME, Monti J, Pellegrino J, et al. Experimental protocol to transplant isolated hepatocytes from rat donor livers to partial hepatectomized recipient ones. Biocell. 2013; 37:95.
15. Solt D, Farber E. New principle for analysis of chemical carcinogenesis. Nature. 1976; 263:701-03.
16. Borbath I, Leclercq I, Abarca-Quinones J, et al. Inhibition of early preneoplastic events in the rat liver by the somatostatin analog lanreotide. Cancer science. 2007; 98:1831-9.
17. Gerlyng P, Seglen PO. Effects of the tumor promoter 2-acetylaminofluorene and of 4-acetylaminofluorene on rat liver growth. Bull Cancer 1990; 77: 461-6.
18. Alvarez ML, Cerliari JP, Monti J, et al. The in vivo apoptotic effect of interferon alfa-2b on rat preneoplastic liver involves Bax protein. Hepatology. 2002; 35:824-33.
19. Imai T, Masui T, Ichinose M, et al. Reduction of glutathione S-transferase P-form mRNA expression in remodeling nodules in rat liver revealed by in situ hybridization. Carcinogenesis. 1997; 18:545-51.
20. Junqueira LCU, Cossermelli WS, Brentani RR. Differential staining of collagen type I, II and III by Sirius Red and polarization microscopy. Arch Histol Jap 1978; 41: 267-74.
21. Seglen PO. Preparation of rat liver cells: III. Enzymatic requirements for tissue dispersion. Exp cell res. 1973; 82:391-8.
22. Gkretsi V, Zhang Y, Tu Y, et al. Physical and functional association of migfilin with cell-cell adhesions. J cell sci. 2005; 118:697-710.
23. Baur H, Kasperek S, Pfaff E. Criteria of viability of isolated liver cells. Hoppe-Seyler's Z. Physiol Chem. 1975; 356:827-38.
24. Higgins A, Anderson RM. Experimental pathology of the liver. Restoration of liver of the White rat following partial surgical removal. Arch Pathol. 1931; 12:186-202.
25. Ascher N. Hepatocyte Transplantation. Liver transplantation. 1995; 1:139-42
26. Strom S, Fisher R, Rubistein W, et al. Transplantation of Human Hepatocytes. Transplant Proc. 1997; 29:2103-6.
27. Nishie M, Tateno C, Utoh R, et al. Hepatocytes from fibrotic liver possess high growth potential in vivo. Cell Transplant. 2009; 18:665–75.
28. Cascales Angosto, M. El extraordinario fenómeno de la regeneración
hepática. Real Academia Anal de Farmacia/Fund. J. Casares Gil 2006, pp. 7-28.
29. Saltykov, SA. The determination of the size distribution of particles in an opaque material for measurement of the size distribution of their sections. In: Elias H (ed.). Proceedings of the Second International Congress for Stereology. Chicago: Springer-Verlag, 1967, p. 163-73
30. Greer JP, Foerster J, Rodger GM, et al. Hemostasis. In: Greer JP, ed. Wintrobe’s Clinical Hematology. Philadelphia, Ph: Kluwer Health/Lippincott Williams & Wilkins; 2009:468-630.
31. Dragan YP, Hully JR, Nakamura J, Mass MJ, Swenberg JA, Pitot HC. Biochemical events during initiation of rat hepatocarcinogenesis. Carcinogenesis 1994; 15: 1451-8.
32. Bannasch P, Klimek F, Mayer D. Early bioenergetic changes in hepatocarcinogenesis: preneoplastic phenotypes mimic responses to insulin and thyroid hormone. J Bioenerg Biomembr 1997; 29: 303-13.
Artículos relacionados

Carta

Hepatocyte transplantation

DOI: 10.17235/reed.2019.6270/2019

Instrucciones para citar
Vera M, Biancardi M, Bottai H, Lugano M, Quiroga A, Pisani G, et all. First approaches for the transplantation of hepatocytes from Wistar rat preneoplastic livers into healthy recipients. 5830/2018


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 524 veces.
Este artículo ha sido descargado 78 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 15/07/2018

Aceptado: 26/10/2018

Prepublicado: 15/02/2019

Publicado: 07/05/2019

Tiempo de revisión del artículo: 96 días

Tiempo de prepublicación: 215 días

Tiempo de edición del artículo: 296 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas